250 related articles for article (PubMed ID: 17212810)
1. Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3.
Heaslet H; Lin YC; Tam K; Torbett BE; Elder JH; Stout CD
Retrovirology; 2007 Jan; 4():1. PubMed ID: 17212810
[TBL] [Abstract][Full Text] [Related]
2. Structural studies of FIV and HIV-1 proteases complexed with an efficient inhibitor of FIV protease.
Li M; Morris GM; Lee T; Laco GS; Wong CH; Olson AJ; Elder JH; Wlodawer A; Gustchina A
Proteins; 2000 Jan; 38(1):29-40. PubMed ID: 10651036
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases.
Lin YC; Beck Z; Morris GM; Olson AJ; Elder JH
J Virol; 2003 Jun; 77(12):6589-600. PubMed ID: 12767979
[TBL] [Abstract][Full Text] [Related]
4. Altered gag polyprotein cleavage specificity of feline immunodeficiency virus/human immunodeficiency virus mutant proteases as demonstrated in a cell-based expression system.
Lin YC; Brik A; de Parseval A; Tam K; Torbett BE; Wong CH; Elder JH
J Virol; 2006 Aug; 80(16):7832-43. PubMed ID: 16873240
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo.
Lee T; Laco GS; Torbett BE; Fox HS; Lerner DL; Elder JH; Wong CH
Proc Natl Acad Sci U S A; 1998 Feb; 95(3):939-44. PubMed ID: 9448264
[TBL] [Abstract][Full Text] [Related]
6. Toward a universal inhibitor of retroviral proteases: comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1, FIV, and EIAV.
Kervinen J; Lubkowski J; Zdanov A; Bhatt D; Dunn BM; Hui KY; Powell DJ; Kay J; Wlodawer A; Gustchina A
Protein Sci; 1998 Nov; 7(11):2314-23. PubMed ID: 9827997
[TBL] [Abstract][Full Text] [Related]
7. Generation of infectious feline immunodeficiency virus (FIV) encoding FIV/human immunodeficiency virus chimeric protease.
Lin YC; Torbett BE; Elder JH
J Virol; 2010 Jul; 84(13):6799-809. PubMed ID: 20410281
[TBL] [Abstract][Full Text] [Related]
8. Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus.
Wlodawer A; Gustchina A; Reshetnikova L; Lubkowski J; Zdanov A; Hui KY; Angleton EL; Farmerie WG; Goodenow MM; Bhatt D
Nat Struct Biol; 1995 Jun; 2(6):480-8. PubMed ID: 7664111
[TBL] [Abstract][Full Text] [Related]
9. Alteration of substrate and inhibitor specificity of feline immunodeficiency virus protease.
Lin YC; Beck Z; Lee T; Le VD; Morris GM; Olson AJ; Wong CH; Elder JH
J Virol; 2000 May; 74(10):4710-20. PubMed ID: 10775609
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for drug and substrate specificity exhibited by FIV encoding a chimeric FIV/HIV protease.
Lin YC; Perryman AL; Olson AJ; Torbett BE; Elder JH; Stout CD
Acta Crystallogr D Biol Crystallogr; 2011 Jun; 67(Pt 6):540-8. PubMed ID: 21636894
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis for the relative substrate specificity of human immunodeficiency virus type 1 and feline immunodeficiency virus proteases.
Beck ZQ; Lin YC; Elder JH
J Virol; 2001 Oct; 75(19):9458-69. PubMed ID: 11533208
[TBL] [Abstract][Full Text] [Related]
12. Crystal structures of the inactive D30N mutant of feline immunodeficiency virus protease complexed with a substrate and an inhibitor.
Laco GS; Schalk-Hihi C; Lubkowski J; Morris G; Zdanov A; Olson A; Elder JH; Wlodawer A; Gustchina A
Biochemistry; 1997 Sep; 36(35):10696-708. PubMed ID: 9271500
[TBL] [Abstract][Full Text] [Related]
13. Selection of drug-resistant feline immunodeficiency virus (FIV) encoding FIV/HIV chimeric protease in the presence of HIV-specific protease inhibitors.
Lin YC; Happer M; Elder JH
J Virol; 2013 Aug; 87(15):8524-34. PubMed ID: 23720716
[TBL] [Abstract][Full Text] [Related]
14. Structural role of the 30's loop in determining the ligand specificity of the human immunodeficiency virus protease.
Swairjo MA; Towler EM; Debouck C; Abdel-Meguid SS
Biochemistry; 1998 Aug; 37(31):10928-36. PubMed ID: 9692985
[TBL] [Abstract][Full Text] [Related]
15. Comparative properties of feline immunodeficiency virus (FIV) and human immunodeficiency virus type 1 (HIV-1) proteinases prepared by total chemical synthesis.
Schnölzer M; Rackwitz HR; Gustchina A; Laco GS; Wlodawer A; Elder JH; Kent SB
Virology; 1996 Oct; 224(1):268-75. PubMed ID: 8862421
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for specificity of retroviral proteases.
Wu J; Adomat JM; Ridky TW; Louis JM; Leis J; Harrison RW; Weber IT
Biochemistry; 1998 Mar; 37(13):4518-26. PubMed ID: 9521772
[TBL] [Abstract][Full Text] [Related]
17. Molecular modeling of the structure of FIV protease.
Gustchina A
Adv Exp Med Biol; 1995; 362():479-84. PubMed ID: 8540361
[No Abstract] [Full Text] [Related]
18. Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1.
Norelli S; El Daker S; D'Ostilio D; Mele F; Mancini F; Taglia F; Ruggieri A; Ciccozzi M; Cauda R; Ciervo A; Barreca ML; Pistello M; Bendinelli M; Savarino A
Curr HIV Res; 2008 Jun; 6(4):306-17. PubMed ID: 18691029
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of human immunodeficiency virus (HIV) type 2 protease in complex with a reduced amide inhibitor and comparison with HIV-1 protease structures.
Tong L; Pav S; Pargellis C; Dô F; Lamarre D; Anderson PC
Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8387-91. PubMed ID: 8378311
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance.
Hong L; Zhang XC; Hartsuck JA; Tang J
Protein Sci; 2000 Oct; 9(10):1898-904. PubMed ID: 11106162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
